ASEAN CSDT Dossier Structure for Singapore Device Submissions

1. Key takeaways

Singapore does not maintain a national dossier format of its own for medical device registration. Submissions are assembled in the ASEAN Common Submission Dossier Template (ASEAN CSDT) structure, and HSA also accepts dossiers organised on the IMDRF table of contents. The guidance in force is GN-17 R5 for general medical devices and GN-18 R5 for in vitro diagnostic medical devices, both issued in October 2026. Electronic filing follows the E-Submission Guide for GMD / IVD for ASEAN CSDT and IMDRF ToC based Submissions in MEDICS R5 of the same month, while the configuration list is governed by Annex 2 for GN-17 and GN-18, List of Configurations, October 2026 edition.

• GN-17 R5 applies to general medical devices and GN-18 R5 to IVD medical devices. Both are October 2026 revisions and are designed to be used as a set with the matching electronic submission guide and configuration annex.
• The dossier is modular. Administrative documents, product description, labelling and instructions for use, design and performance verification, manufacturing information, Essential Principles conformity, risk management, clinical evidence and post-market surveillance form discrete blocks that reviewers navigate independently.
• Classification rests on GN-13 R2.1 for general devices and GN-14 R3 for IVD devices; grouping rests on GN-12-1 R3 of June 2026 and GN-12-2 R2. Both decisions are taken before the dossier text is drafted, because they determine which configurations are declared.
• Under the Abridged and Expedited routes the pre-clinical and clinical sections may be filed as summaries that point to the assessment conclusions of the reference agency. A summary is not an omission: the underlying evidence must remain retrievable on request.
• Dossier language is English. No translation certification and no apostille chain is required, removing a workstream that applies in several neighbouring markets.

2. Legal basis

GN-17 R5 sets out how a product registration submission for a general medical device is prepared using the ASEAN CSDT. GN-18 R5 performs the same function for IVD medical devices. The two documents are revised in parallel and share the same administrative architecture; the divergence sits in the technical modules, where an IVD dossier replaces device verification content with analytical and clinical performance content. The instruments below together define the filing requirement, and none can be substituted by an earlier revision.

Under GN-17 R5 the submission is normally organised into the module structure reproduced below. The sequence matters less than completeness: reviewers locate evidence through the module headings, and an incomplete block reads as an absent block.

Two consequences follow. The administrative block is not a formality: a defective letter of authorisation or an expired quality management certificate stops the review before any technical content is reached. And the technical blocks are cross-referenced rather than self-contained, since the Essential Principles checklist points into the verification reports while the clinical evaluation points into the risk management file and the post-market data.

3. Expert insights

The value of CSDT is portability, not standardisation. For a company that will only ever sell in Singapore, the CSDT is simply a format requirement and nothing more. For a company building a Southeast Asian portfolio, it is the lever that reduces dossier preparation from one set per market to one master set plus a localisation layer per market. Our standard approach in multi-country programmes follows that logic exactly: build a single master dossier on the CSDT skeleton, then add a thin market-specific layer for administrative documents, labelling and language.

Under the Abridged and Expedited routes the pre-clinical and clinical chapters may be submitted as summaries. This is the substantive documentary benefit of the simplified and accelerated pathways. The applicant may rely on the assessment conclusions of the reference agency and present those two parts in summary form. The qualification matters: a summary still has to point, completely and traceably, to the evidence it depends on, and reviewers accept a short chapter only when that route is obvious from the page.

The configuration list in Annex 2 is where the grouping decision lands, and it must be fixed before the CSDT text is finalised. The execution order we use is grouping strategy, then configuration list, then dossier body. Reversing that order produces the familiar failure mode in which the technical file and the configuration list contradict each other, and the contradiction surfaces as a deficiency letter rather than as an internal finding. The configuration list is short, but it constrains scope statements, labelling variants and the verification matrix at the same time.

R5 is the October 2026 revision and was released alongside GN-15 R15. HSA updated GN-15 to R15, GN-17 to R5, GN-18 to R5 and the electronic submission guide in the same cycle. The practical reading is that format and pathway rules were revised as a package. Pairing a new GN-15 with an old GN-17 produces a dossier that satisfies neither document cleanly, so the complete current set is downloaded once, at kick-off.

Device documents must be in English, with no translation and no notarisation or apostille chain. Singapore accepts English source documents as filed. There is no requirement for certified translation and no legalisation chain, which is a sharp contrast with Indonesia, Thailand and Vietnam. This is where Singapore saves the most calendar time in the documentation phase, and where unnecessary spend most often appears.

4. Practical recommendations

• Download the complete current guidance set at kick-off: GN-15, GN-17 or GN-18, Annex 2 and the E-Submission Guide must all be the matching revisions, and the versions should be recorded in the project file.
• Fix grouping and the configuration list before drafting the dossier body, so that scope statements, labelling variants and the verification matrix are written against a settled structure.
• Build the dossier as a master plus localisation layer even when Singapore is the only current market, because the marginal cost of structuring it that way is small and the reuse value is high.
• Use summary chapters fully on the Abridged and Expedited routes, but keep the complete referenced evidence assembled and indexed so that a query can be answered quickly.
• Do not commission translation certification or notarisation for a Singapore filing. English source documents are accepted as they are, and the extra legalisation step adds cost without adding acceptability.

5. Verification checklist

• □ Confirmed whether GN-17 R5 (general device) or GN-18 R5 (IVD) applies to the product.
• □ Downloaded the matching E-Submission Guide R5 and Annex 2 List of Configurations.
• □ Grouping strategy and configuration list signed off before the dossier body was drafted.
• □ All nine modules populated: administrative, description, labelling, verification, manufacturing, principles, risk, clinical and post-market surveillance.
• □ Summary-style chapters prepared where the Abridged or Expedited route is used, with traceable references to the underlying evidence.
• □ Entire dossier in English, with no unnecessary translation certification or notarisation attached.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com